心力衰竭生物标志物临床应用中国专家共识  

Chinese Expert Consensus on Clinical Application of Biomarkers for Heart Failure

作　　者：中国医师协会心力衰竭专业委员会 国家心血管病专家委员会心力衰竭专业委员会 中华心力衰竭和心肌病杂志编辑委员会 张宇辉 张健 唐其柱[3] 周洲 陈雨意 Chinese Heart Failure Association of Chinese Medical Doctor Association;National Expert Committee on Cardiovascular Diseases and Professional Committee on Heart Failure;Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy

机构地区：[1]不详 [2]中国医学科学院阜外医院 [3]武汉大学人民医院

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2022年第3期175-192,共18页Chinese Journal of Heart Failure and Cardiomyopathy

摘　　要：心力衰竭(心衰)的多种病理生理改变均涉及相关生物标志物的表达,生物标志物在心衰预测、诊断、指导治疗及预后评估方面发挥着重要的作用。监测心衰患者生物标志物水平是心衰管理的重要部分。本共识结合国内外最新研究结果和我国实践经验,对目前心衰生物标志物临床应用进行总结,旨在指导和规范我国心衰患者的生物标志物管理,从而改善心衰患者的诊疗和预后。The pathophysiologic mechanisms of heart failure involve the expression of associated biomarkers,which may play an important role in the prediction,diagnosis,treatment guidance and prognosis for heart failure.Monitoring the levels of biomarkers is of importance in the management of patients with heart failure.This expert consensus summarizes the clinical application of biomarkers for heart failure according to the updated research results home and abroad and the practical experience of our country,with the aim to guide and standardize the management of biomarkers,so as to improve the diagnosis,treatment and prognosis of patients with heart failure in China.

关 键 词：心力衰竭 生物标志物 利钠肽 心肌肌钙蛋白 

分 类 号：R541.6[医药卫生—心血管疾病]